ClinicalTrials.gg
CompletedNCT03700658Updated Jan 26, 2022Results posted

A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046

A Phase 1 interventional study of TV-46046 and Depo-subQ 104 in Contraception, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 1 site in Dominican Republic. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-26.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The purpose of this study is to evaluate the local tolerability associated with the SC administration of TV-46046, and inform next steps of the TV-46046 development program.

Read the detailed description

Eligible participants will be enrolled and receive 1 of each of the 4 SC study injections in each abdominal quadrant approximately 1 hour apart: 120 milligrams (mg)/0.3 milliliter (mL) of TV-46046, 60 mg/0.3 mL of 1:1 saline diluted TV-46046, 0.3 mL of TV-46046 Placebo and 104 mg/0.65 mL Depo-subQ 104 per the assigned sequence.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a low risk of pregnancy (that is, sterilized, in exclusively same-sex partnership, in menopause and/or , abstinent, in a monogamous relationship with vasectomized partner, using nonhormonal intrauterine device [IUD], or consistent use of condoms)
  • Participant is not pregnant and does not have desire to become pregnant in the subsequent 18 months
  • Participant had a normal mammogram within the last year, if 40 years or older
  • Participant has no skin disorders or skin allergies

    • Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Participant has hypertension
  • Participant has ischemic heart disease or a history of ischemic heart disease
  • Participant has a history of stroke
  • Participant has a history of thromboembolic event(s)
  • Participant has systemic lupus erythematosus
  • Participant has rheumatoid arthritis and is undergoing therapy
  • Participant has migraine with aura
  • Participant has unexplained vaginal bleeding
  • Participant has diabetes
  • Participant has a strong family history of breast cancer
  • Participant has cervical cancer or a history of cervical cancer
  • Participant has severe cirrhosis (decompensated) or liver tumors
  • Participant has known significant renal disease
  • Participant has a history of diagnosed clinical depression or bipolar disorder, with or without suicidal ideation, and/or history of suicide attempt
  • Participant is currently using hormonal
  • Participant had an injection of DMPA (Depo-Provera CI or Depo-subQ 104) in the past 12 months; or combined injectable in the last 3 months
  • Participant is chronically using pain medication
  • Participant has a plan to move to another location in the next 18 months

    • Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    TV-46046 Undiluted

    Participants will receive TV-46046 undiluted (120 mg/0.3 mL of 400 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.

    Drug: TV-46046

  • Experimental
    TV-46046 Diluted

    Participants will receive TV-46046 saline-diluted (60 mg/0.3 mL of 200 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.

    Drug: TV-46046

  • Placebo comparator
    TV-46046 Placebo

    Participants will receive TV-46046 placebo (0.3 mL) SC injection in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.

    Drug: TV-46046 Placebo

  • Active comparator
    Depo-subQ 104

    Participants will receive Depo-subQ 104 (medroxyprogesterone acetate injectable suspension; 104 mg/0.65 mL) SC injection as a reference formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.

    Drug: Depo-subQ 104

Interventions

  • TV-46046 will be administered per dose and schedule specified in the arm.

  • Depo-subQ 104 will be administered per dose and schedule specified in the arm.

    Also known as: Medroxyprogesterone acetate injectable suspension, Depo-subQ Provera 104®

  • DrugTV-46046 Placebo

    TV-46046 Placebo will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain)

    ISRs were assessed by self-reports and direct observation for each injection at least twice on the day of injection. ISRs included erythema (redness), swelling, pruritus (itching), bleeding, bruising, injection site discoloration (for example, hypopigmentation), or atrophy (that is, dimple).

    Time frame: Day 0 (immediately after and 1 hour after the injection) up to Month 18

Secondary outcomes

  1. Injection Site Pain Score, as Assessed by Numerical Rating Scale (NRS)

    Participants assessed their injection site pain using an 11-point NRS (0 = no pain at all; 10 = worst pain). Higher scores denote worse outcome.

    Time frame: Day 0 (Immediately after and 1 hour after injection)

  2. Participant's Perception of Pain, as Assessed by an Overall Ranking of the 4 Study Injections From Least to Most Painful

    Each participant was asked to rank the injections according to overall pain from least (score = 1) to most (score = 4) painful. If a participant could not rank all of her injections from least to most painful or could not uniquely identify which injection was the most painful, then her responses were appropriately weighted across groups (for example, if a participant ranked all 4 treatments as equally most painful, then that participant contributed a score of 0.25 to each group when assessing the distribution of the most painful injection and in the event of a tie between 2 rankings, 0.5 was assigned to each tied ranking).

    Time frame: Day 0 (1 hour after injection)

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were considered treatment emergent if (a) the onset occurred on or after the time of first injection or (b) an event had an onset prior to the first injection but increased in severity after administration of the injection. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Day 0 up to Month 18

07

Results

Posted Jan 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneOverall Study
Started27
Received at least 1 dose of study drug27
Completed27
Not completed0

Outcome measures

PrimaryNumber of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain)

ISRs were assessed by self-reports and direct observation for each injection at least twice on the day of injection. ISRs included erythema (redness), swelling, pruritus (itching), bleeding, bruising, injection site discoloration (for example, hypopigmentation), or atrophy (that is, dimple).

Time frame:
Day 0 (immediately after and 1 hour after the injection) up to Month 18
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain)
ParticipantsTV-46046 UndilutedTV-46046 DilutedTV-46046 PlaceboDepo-subQ 104
Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain)12608
SecondaryInjection Site Pain Score, as Assessed by Numerical Rating Scale (NRS)

Participants assessed their injection site pain using an 11-point NRS (0 = no pain at all; 10 = worst pain). Higher scores denote worse outcome.

Time frame:
Day 0 (Immediately after and 1 hour after injection)
Reported as:
Mean · units on a scale
Injection Site Pain Score, as Assessed by Numerical Rating Scale (NRS)
units on a scaleTV-46046 UndilutedTV-46046 DilutedTV-46046 PlaceboDepo-subQ 104
Immediately after injection2.1 ± 1.721.9 ± 1.463.3 ± 2.151.2 ± 1.40
1 hour after injection0.2 ± 0.500.2 ± 0.500.6 ± 1.000.1 ± 0.29
SecondaryParticipant's Perception of Pain, as Assessed by an Overall Ranking of the 4 Study Injections From Least to Most Painful

Each participant was asked to rank the injections according to overall pain from least (score = 1) to most (score = 4) painful. If a participant could not rank all of her injections from least to most painful or could not uniquely identify which injection was the most painful, then her responses were appropriately weighted across groups (for example, if a participant ranked all 4 treatments as equally most painful, then that participant contributed a score of 0.25 to each group when assessing the distribution of the most painful injection and in the event of a tie between 2 rankings, 0.5 was assigned to each tied ranking).

Time frame:
Day 0 (1 hour after injection)
Reported as:
Number · frequency (number of times) of ranking
Participant's Perception of Pain, as Assessed by an Overall Ranking of the 4 Study Injections From Least to Most Painful
frequency (number of times) of rankingTV-46046 UndilutedTV-46046 DilutedTV-46046 PlaceboDepo-subQ 104
Pain Rank 14549
Pain Rank 28.58.505
Pain Rank 34.54.567
Pain Rank 454121
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were considered treatment emergent if (a) the onset occurred on or after the time of first injection or (b) an event had an onset prior to the first injection but increased in severity after administration of the injection. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Day 0 up to Month 18
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsOverall Study
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)23

Adverse events

Collected over Day 0 up to Month 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Follow-up After Treatment0/27 (0%)1/27 (3.7%)18/27 (66.7%)
TV-46046 Undiluted0/27 (0%)0/27 (0%)0/27 (0%)
TV-46046 Diluted0/27 (0%)0/27 (0%)1/27 (3.7%)
TV-46046 Placebo0/27 (0%)0/27 (0%)2/27 (7.4%)
Depo-subQ 1040/27 (0%)0/27 (0%)0/27 (0%)
Most frequent serious events
Most frequent serious events
EventFollow-up After TreatmentTV-46046 UndilutedTV-46046 DilutedTV-46046 PlaceboDepo-subQ 104
CholelithiasisHepatobiliary disorders1/270/270/270/270/27
Most frequent other events
Most frequent other events
EventFollow-up After TreatmentTV-46046 UndilutedTV-46046 DilutedTV-46046 PlaceboDepo-subQ 104
HeadacheNervous system disorders8/270/270/270/270/27
AcarodermatitisInfections and infestations3/270/270/270/270/27
InfluenzaInfections and infestations3/270/270/270/270/27
Urinary tract infectionInfections and infestations3/270/270/270/270/27
DizzinessNervous system disorders3/270/270/270/270/27
Breast painReproductive system and breast disorders3/270/270/270/270/27
Abdominal pain lowerGastrointestinal disorders2/270/270/270/270/27
Injection site painGeneral disorders0/270/271/272/270/27
VulvitisInfections and infestations2/270/270/270/270/27
DysmenorrhoeaReproductive system and breast disorders2/270/270/270/270/27

Baseline characteristics

The treated analysis set included all participants who received at least 1 of the 4 study drug injections.

Age, Continuous
Age, Continuous(years)Overall Study
Mean35.7 ± 6.20
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female27
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study
Race — Biracial26
Race — Black or African American1
08

Study locations

1 site
  • Teva Investigational Site 1
    Santo Domingo, Dominican Republic
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Oct 2020, 20 months.

Results were first posted in Jan 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2018
First posted
Oct 9, 2018
StartActual
Jan 15, 2019
Primary completionActual
Oct 2, 2020
CompletionActual
Oct 2, 2020
Results first posted
Jan 26, 2022
Last update
Jan 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03700658
Collaborators
FHI 360
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Jan 15, 2019
Primary completion
Oct 2, 2020
Completion
Oct 2, 2020
Results posted
Jan 26, 2022
Last update
Jan 26, 2022

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Medroxyprogesterone Acetate

Start the discussion